SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science, this issue p. 1227 Antibodies generated after mild to moderate SARS-CoV-2 infection are neutralizing and relatively stable for at least 5 months. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.

中文翻译：

---

针对 SARS-CoV-2 感染的强效中和抗体持续数月

SARS-CoV-2 抗体持续存在 随着全球每天 COVID-19 病例数不断增加，对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的体液免疫反应的性质仍不确定。瓦恩伯格等人。使用由 30,000 多名具有轻度至中度 COVID-19 症状的感染者组成的队列来确定抗 SARS-CoV-2 抗体反应的稳健性和持久性。他们发现，针对 SARS-CoV-2 刺突蛋白的中和抗体滴度在感染后至少持续了 5 个月。尽管需要对该队列进行持续监测以确认这种反应的持续时间和效力，但这些初步结果表明，再感染的可能性可能低于目前所担心的。科学，这个问题 p。1227 轻度至中度 SARS-CoV-2 感染后产生的抗体具有中和作用且相对稳定至少 5 个月。严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 已引起全球大流行，数百万人被感染，超过 100 万人死亡。关于病毒抗体反应的稳健性、功能性和寿命的问题仍未得到解答。在这里，基于在纽约市西奈山卫生系统筛选的 30,082 人的数据集，我们报告说，绝大多数患有轻度至中度 COVID-19 的感染者都经历了针对病毒尖峰的强大免疫球蛋白 G 抗体反应蛋白质。我们还表明，滴度在至少约 5 个月的时间内相对稳定，并且抗尖峰结合滴度与真正 SARS-CoV-2 的中和显着相关。我们的数据表明，超过 90% 的血清转化剂产生可检测的中和抗体反应。这些滴度在感染后数月内保持相对稳定。